IDEXX LABORATORIES INC /DE is 25.4x more valuable than Intellia Therapeutics, Inc. by market capitalization ($43.93 B vs $1.73 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | NTLA | IDXX |
|---|---|---|
| Market cap | $1.73 B | $43.93 B |
| US-listed rank | #2213 | #351 |
| Revenue (latest FY) | $67.67M | $4.30B |
| Net income (latest FY) | -$412.69M | $1.06B |
| Net margin | -609.9% | 24.6% |
| P/E (trailing FY) | - | 41.5 |
| SEC filings | 687 | 2,148 |
IDEXX LABORATORIES INC /DE is 25.4x more valuable than Intellia Therapeutics, Inc. by market capitalization ($43.93 B vs $1.73 B).
In their latest fiscal years, Intellia Therapeutics, Inc. reported $67.67M in revenue while IDEXX LABORATORIES INC /DE reported $4.30B.
Full pages: Intellia Therapeutics, Inc. and IDEXX LABORATORIES INC /DE, or browse the full rankings.